Clinical trial
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV…
NCT00397982 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00397982 |
|---|---|
| Title | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma |
| Official title | A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma |
| Acronym | Mel47 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Fox Chase Cancer Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | Bevacizumab, Laboratory Biomarker Analysis, Temsirolimus, Therapeutic Conventional Surgery |
| Enrollment | 17 |
| Start date | Jan 1, 2008 |
| Primary completion | Jul 1, 2013 |
| Completion | Jul 1, 2013 |
| First posted | Nov 10, 2006 |
| Last update posted | Jun 9, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: